| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
118,790,000 |
| Market
Cap: |
42.71(M) |
| Last
Volume: |
19,275,386 |
Avg
Vol: |
8,941,637 |
| 52
Week Range: |
$0.3595 - $0.3595 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Novavax is a biotechnology company that promotes improved global health through the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Co.'s vaccine candidates, including both its coronavirus vaccine candidate, NVX-CoV2373, and its primary influenza vaccine candidate, NanoFlu, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 and NanoFlu include the use of Co.'s proprietary Matrix-M™ adjuvant.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
6,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$43,042 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
47,312 |
47,312 |
47,312 |
47,312 |
| Total Sell Value |
$657,637 |
$657,637 |
$657,637 |
$657,637 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
1 |
1 |
1 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Trizzino John |
SVP, CBO and CFO |
• – – |
2019-09-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,143 |
12,091 |
|
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2019-09-08 |
4 |
D |
$5.50 |
$13,937 |
D/D |
(2,534) |
9,743 |
|
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2019-09-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,608 |
12,277 |
|
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2019-05-13 |
4 |
B |
$5.85 |
$5,850 |
D/D |
1,000 |
74,386 |
2.74 |
- |
|
| King Rachel K. |
Director |
– • – |
2019-03-27 |
4 |
B |
$0.53 |
$23,311 |
I/I |
44,000 |
22,000 |
2.1 |
- |
|
| King Rachel K. |
Director |
– • – |
2019-03-27 |
4 |
B |
$0.53 |
$22,252 |
D/D |
42,000 |
42,000 |
2.39 |
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2019-01-31 |
4 |
B |
$0.88 |
$11,588 |
D/D |
13,168 |
73,386 |
2.74 |
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2018-07-31 |
4 |
B |
$0.88 |
$11,446 |
D/D |
13,007 |
60,218 |
2.74 |
- |
|
| Erck Stanley C |
President and CEO |
• • – |
2018-05-14 |
4 |
B |
$1.65 |
$164,620 |
D/D |
100,000 |
328,279 |
2.81 |
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2018-05-14 |
4 |
B |
$1.64 |
$32,800 |
D/D |
20,000 |
47,211 |
2.74 |
- |
|
| Trizzino John |
SVP, CBO and CFO |
• – – |
2018-05-14 |
4 |
B |
$1.64 |
$81,995 |
D/D |
50,000 |
138,965 |
2.74 |
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2018-01-31 |
4 |
B |
$0.88 |
$11,250 |
D/D |
12,784 |
27,211 |
2.74 |
- |
|
| Erck Stanley C |
President and CEO |
• • – |
2017-11-09 |
4 |
B |
$1.13 |
$113,050 |
D/D |
100,000 |
228,279 |
2.81 |
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2017-11-09 |
4 |
B |
$1.13 |
$11,300 |
D/D |
10,000 |
14,427 |
2.74 |
- |
|
| Young James F |
Director |
– • – |
2017-08-31 |
4 |
S |
$1.06 |
$184,870 |
D/D |
(175,000) |
0 |
|
- |
|
| Phillips Barclay A |
SVP, Chief Financial Officer |
• – – |
2017-07-31 |
4 |
B |
$0.89 |
$1,831 |
D/D |
2,057 |
38,669 |
2.66 |
- |
|
| Mcmanus Michael A Jr |
Director |
– • – |
2017-05-12 |
4 |
B |
$0.97 |
$19,396 |
D/D |
20,000 |
277,590 |
2.39 |
- |
|
| Douglas Richard |
Director |
– • – |
2017-05-11 |
4 |
B |
$0.93 |
$185,780 |
D/D |
200,000 |
550,000 |
2.39 |
- |
|
| Mcmanus Michael A Jr |
Director |
– • – |
2017-05-11 |
4 |
B |
$0.84 |
$8,400 |
D/D |
10,000 |
257,590 |
2.39 |
- |
|
| Phillips Barclay A |
SVP, Chief Financial Officer |
• – – |
2017-05-11 |
4 |
B |
$0.84 |
$20,950 |
D/D |
25,000 |
36,612 |
2.74 |
- |
|
| Erck Stanley C |
President and CEO |
• • – |
2017-05-11 |
4 |
B |
$0.84 |
$41,980 |
D/D |
50,000 |
128,279 |
2.81 |
- |
|
| Young James F |
Director |
– • – |
2017-03-14 |
4 |
S |
$1.39 |
$138,980 |
D/D |
(100,000) |
175,000 |
|
- |
|
| Phillips Barclay A |
SVP, Chief Financial Officer |
• – – |
2017-01-31 |
4 |
B |
$1.12 |
$1,829 |
D/D |
1,633 |
11,612 |
2.66 |
- |
|
| Trizzino John |
SVP, Commercial Operations |
• – – |
2017-01-31 |
4 |
B |
$1.12 |
$3,809 |
D/D |
3,401 |
88,965 |
2.66 |
- |
|
| Herrmann John A Iii |
SVP, General Counsel |
• – – |
2017-01-31 |
4 |
B |
$1.12 |
$5,555 |
D/D |
4,960 |
7,072 |
2.74 |
- |
|
604 Records found
|
|
Page 15 of 25 |
|
|
